Paracold may be available in the countries listed below.
Ingredient matches for Paracold
Paracetamol is reported as an ingredient of Paracold in the following countries:
- Vietnam
International Drug Name Search
Paracold may be available in the countries listed below.
Paracetamol is reported as an ingredient of Paracold in the following countries:
International Drug Name Search
Ramipril Ivax may be available in the countries listed below.
Ramipril is reported as an ingredient of Ramipril Ivax in the following countries:
International Drug Name Search
Acamol may be available in the countries listed below.
Paracetamol is reported as an ingredient of Acamol in the following countries:
International Drug Name Search
Menitazine may be available in the countries listed below.
Betahistine dimesilate (a derivative of Betahistine) is reported as an ingredient of Menitazine in the following countries:
International Drug Name Search
Deratin Comprimidos may be available in the countries listed below.
Chlorhexidine dihydrochloride (a derivative of Chlorhexidine) is reported as an ingredient of Deratin Comprimidos in the following countries:
International Drug Name Search
Fluoxetin may be available in the countries listed below.
Fluoxetine is reported as an ingredient of Fluoxetin in the following countries:
Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetin in the following countries:
International Drug Name Search
Captopril/Hydrochlorothiazide Qualimed may be available in the countries listed below.
Captopril is reported as an ingredient of Captopril/Hydrochlorothiazide Qualimed in the following countries:
Hydrochlorothiazide is reported as an ingredient of Captopril/Hydrochlorothiazide Qualimed in the following countries:
International Drug Name Search
Metoserpate Hydrochloride may be available in the countries listed below.
Metoserpate Hydrochloride (BANM, USAN) is also known as Metoserpate (Rec.INN)
International Drug Name Search
Glossary
BANM | British Approved Name (Modified) |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Ipacillin may be available in the countries listed below.
Ampicillin is reported as an ingredient of Ipacillin in the following countries:
International Drug Name Search
Ivermec may be available in the countries listed below.
Ivermectin is reported as an ingredient of Ivermec in the following countries:
International Drug Name Search
Sulfatrim Pediatric is a brand name of sulfamethoxazole/trimethoprim, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Sulfatrim Pediatric:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sulfatrim Pediatric. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Sulfatrim Pediatric.
Cefurox Basics may be available in the countries listed below.
Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Cefurox Basics in the following countries:
International Drug Name Search
Cipralan may be available in the countries listed below.
Cibenzoline is reported as an ingredient of Cipralan in the following countries:
Cibenzoline succinate (a derivative of Cibenzoline) is reported as an ingredient of Cipralan in the following countries:
International Drug Name Search
Generic Name: tositumomab (TOE si too MOE mab)
Brand Names: Bexxar Dosimetric, BexxarTherapeutic
Tositumomab is a monoclonal antibody that is linked with radioactive iodine I-131. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.
Tositumomab is used to treat certain forms of non-Hodgkin's lymphoma. It is usually given after other medications have been tried without successful treatment.
Tositumomab may also be used for other purposes not listed in this medication guide.
Before you receive tositumomab, tell your doctor if you have kidney disease or severe bone marrow suppression.
Tositumomab can be harmful to an unborn baby whether the father or the mother receives this medication at the time of conception. Use effective birth control to prevent pregnancy during your treatment, whether you are a man or a woman. Continue using birth control for at least 12 months after you have received tositumomab.
Tositumomab can be harmful to an unborn baby whether the father or the mother receives this medication at the time of conception. Use effective birth control to prevent pregnancy during your treatment, whether you are a man or a woman. Continue using birth control for at least 12 months after you have received tositumomab.
Some people treated with tositumomab later developed leukemia or other cancers. However, it has not been determined whether this medication actually increases the risk of causing other cancers. Talk with your doctor about your individual risk.
The tositumomab treatment is usually given in two steps over a span of 7 days. In the first treatment step, you will receive the two injections just before you undergo an x-ray scan of your entire body. This scan will show your doctor how well the radioactive ingredients of the tositumomab injections are circulating throughout your body. You may receive at least 2 more scans over the next 6 or 7 days.
Based on the results of your scans, your doctor will determine whether or not to give the second step of tositumomab treatment, and how large your dose should be.
In step 2 of the treatment, you will again receive the two injections one at a time. These injections are considered your therapeutic dose. The 2-step tositumomab treatment is usually given only once, so you are not likely to receive a second course of treatment with this medication.
Tositumomab can increase your risk of developing hypothyroidism (underactive thyroid). Hypothyroidism can be treated with daily thyroid replacement medication.
Tositumomab can cause you to have unusual results with certain medical tests. You may also have an allergic reaction to diagnostic tests or treatments using mouse proteins or monoclonal antibodies. Tell any doctor who treats you that you have been treated with tositumomab.
Since tositumomab is given in a controlled setting by a healthcare professional, it is not likely that you will miss a dose.
An overdose of this medication is very unlikely to occur.
Avoid sports or activities that may increase your risk of bleeding or injury. Use a soft toothbrush to keep your gums from bleeding. Take extra care not to cut yourself while shaving.
When cleaning any spills of bodily fluid, use only disposable cleaning cloths that can be flushed down a toilet. Ask your doctor or health department how to dispose of any bodily fluid spills that cannot be flushed down a toilet.
To protect others from exposure to the radioactive matter in your body, try to stay at least 6 feet away from other people, especially children or pregnant women. Follow these steps for several days after your tositumomab treatment ends:
Avoid crowds and public places.
Avoid traveling on long trips.
Do not share a bed or bathroom with another person.
Sit on the toilet while urinating and flush 3 times with the lid down after use.
Always wash your hands after using the bathroom.
Do not share a towel, wash cloth, or toothbrush with another person.
Do not share drinking glasses, plates, or silverware.
Wait at least 1 week before washing any of the clothing and bed or bath linens you have used during the week after your treatment. Keep these items separate from the laundry of other people in your home.
Wash your clothing and other items separately from other laundry in your home.
Call your doctor at once if you have a serious side effect such as:
pale skin, easy bruising or bleeding, unusual weakness;
black, bloody, or tarry stools;
blood in your urine;
fever, chills, sore throat, body aches, flu symptoms;
cough with yellow or green mucus; or
stabbing chest pain, feeling short of breath.
Less serious side effects may include:
decreased energy;
weight gain;
headache;
joint or muscle pain;
feeling weak or irritable;
increased thirst and hot, dry skin;
nausea, vomiting, diarrhea, stomach pain;
loss of appetite;
mild itching or skin rash;
runny or stuffy nose; or
pain, itching, swelling, or redness around your IV needle.
Amlodipin AL may be available in the countries listed below.
Amlodipine mesilate (a derivative of Amlodipine) is reported as an ingredient of Amlodipin AL in the following countries:
International Drug Name Search
Lovask may be available in the countries listed below.
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Lovask in the following countries:
International Drug Name Search
Benzylpenicillin benzathine (a derivative of Benzylpenicillin) is reported as an ingredient of Permapen in the following countries:
International Drug Name Search
Relieving congestion due to colds, flu, hay fever, and other allergies. It may also be used for other conditions as determined by your doctor.
Drixoral Non-Drowsy Sustained-Release Capsules are a decongestant. It works by reducing swelling and constricting blood vessels in the nasal passages, allowing you to breathe more easily.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Drixoral Non-Drowsy Sustained-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Drixoral Non-Drowsy Sustained-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Drixoral Non-Drowsy Sustained-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Drixoral Non-Drowsy Sustained-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Drixoral Non-Drowsy Sustained-Release Capsules.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Difficulty urinating; dizziness; headache; nausea; nervousness; restlessness; sleeplessness; stomach irritation.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Drixoral Non-Drowsy side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include confusion; hallucinations; irregular or unusually slow or rapid heartbeat; rapid breathing; seizures.
Store Drixoral Non-Drowsy Sustained-Release Capsules at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Drixoral Non-Drowsy Sustained-Release Capsules out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Drixoral Non-Drowsy Sustained-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Fluoxetina Cinfa may be available in the countries listed below.
Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetina Cinfa in the following countries:
International Drug Name Search
Ezetim may be available in the countries listed below.
Ezetimibe is reported as an ingredient of Ezetim in the following countries:
International Drug Name Search
Medinol may be available in the countries listed below.
UK matches:
Paracetamol is reported as an ingredient of Medinol in the following countries:
International Drug Name Search
Glossary
SPC | Summary of Product Characteristics (UK) |
Rifampicina Iqfarma may be available in the countries listed below.
Rifampicin is reported as an ingredient of Rifampicina Iqfarma in the following countries:
International Drug Name Search